Background: This prospective, case-series study aimed to assess the clinical effectiveness of plasma rich in growth factors (PRGF) in patients with chronic low back pain (LBP) and to identify the features of the responsive patients. Materials & methods: PRGF was injected into the intervertebral disc, epidural space and/or facet and sacroiliac joints of 32 patients with chronic LBP. The efficacy of the treatment was assessed by algo-functional scores after 3 and 6 months. Results: Overall, the patients did not ameliorate after PRGF treatment, although eight patients showed an algo-functional improvement. They were mainly males treated at two sites who were younger, less sedentary and with fewer musculoskeletal co-morbidities than the nonresponders. Conclusion: PRGF is a potential treatment in a specific subpopulation of difficult-to-treat patients affected by chronic LBP.
Keywords: back pain; orthobiologics; plasma rich in growth factors; platelet rich plasma; regenerative medicine; spinal pain.
Plain language summary In this study, 32 patients with chronic low back pain (LBP) were treated with plasma rich in growth factors (PRGF) to evaluate its clinical efficacy up to 6 months. The results showed that, analyzing the total cohort, the PRGF did not ameliorate the patients' conditions. However, eight patients responded to the treatment by showing an algo-functional improvement. They were mainly males, younger than 50 years/old, with active lifestyle habits, and with less musculoskeletal co-morbidities than the patients who did not respond. Best results were obtained when PRGF was injected at one intervertebral disc plus facet joints at the corresponding level. In conclusion, PRGF may be an effective treatment if used in patients with specific characteristics.